CHICAGO, July 17, 2024 -- The global digital pathology market is expected to grow from USD 1.1 billion in 2024 to USD 2.0 billion by 2029, at a CAGR of 13.1%. The digital pathology market is primarily driven by the increasing adoption of digital pathology solutions by healthcare providers and laboratories, alongside the global expansion of telepathology services, which improves access to expert pathology services in remote or underserved areas. This growth is supported by advancements in technology, including whole-slide imaging (WSI), image analysis software, and artificial intelligence (AI), which enhance diagnostic precision and operational efficiency. However, integrating digital pathology systems into existing laboratory workflows remains a challenge. The rise of AI and machine learning applications presents significant opportunities, aiding pathologists in identifying abnormalities and improving treatment strategies. The market ecosystem includes entities delivering digital pathology solutions to end users, with software being the fastest-growing segment due to advancements in AI and machine learning. Human pathology registers the highest growth rate driven by the rising prevalence of chronic diseases like cancer. The drug discovery segment accounted for the largest share in 2023, benefiting from digital pathology's ability to analyze vast datasets accurately. Pharmaceutical and biotechnology companies are the largest end users, utilizing digital pathology for extensive research and development. North America dominates the market due to its advanced healthcare infrastructure and significant investment in healthcare technologies. Key market players include Fujifilm Holdings Corporation, Danaher Corporation, Koninklijke Philips N.V., PathAI, and F. Hoffmann-La Roche Ltd.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844
Browse in-depth TOC on "Digital Pathology Market"
248 - Tables
47 - Figures
325 - Pages
DANAHER CORPORATION (US): Leader in Digital Pathology Solutions
Danaher Corporation, through its subsidiary Leica Biosystems, has established itself as a strong player in the digital pathology market, offering a comprehensive portfolio from biopsy to diagnosis across radiology, pathology, surgery, and oncology. Strategic partnerships have significantly bolstered its market position. In March 2023, Danaher partnered with Paige, a global leader in digital pathology solutions and clinical AI applications, to enhance digital pathology workflows in hospitals and laboratories. The company also collaborates with the European Society for Digital and Integrative Pathology (ESDIP) to promote digital pathology adoption across Europe, fostering continuous growth and innovation in diagnostic technologies.
KONINKLIJKE PHILIPS N.V. (Netherlands): Prominent Player in Digital Pathology
Philips is a prominent player in the digital pathology market, offering solutions that enhance efficiency, collaboration, and diagnostic accuracy for pathologists globally. Philips' digital pathology solution transitions pathologists from traditional microscopy to digital workflows, achieving efficiency gains of 15-20% per case. By digitizing pathology processes, Philips facilitates remote and collaborative environments, addressing the global shortage of trained pathologists and enabling multidisciplinary collaboration. Their solution supports remote consultation, real-time case sharing, and multidisciplinary discussions among clinical teams, enhancing comprehensive patient care. With insights from over 300 customers and 20 hospital pathology laboratories, Philips continually refines its solution to meet diverse healthcare provider needs.
HAMAMATSU PHOTONICS K.K. (Japan): Key Player in Digital Pathology
Hamamatsu
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
